1-benzenesulphonyl-2-oxo-5-alkoxypyrrolidines and medical methods of use thereof
Memory enhancing 1-(benzenesulfonyl)-2-oxo-5-alkoxy-pyrrolidines are prepared by alkylation of the corresponding pyrrolidones or pyrrolidone precursors.
Latest Roussel Uclaf Patents:
- New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions
- Active phospholipids as a vector for active molecules
- Arabidepsi thaliana proteins having .DELTA.-5,7-sterol-.DELTA.-7-reductase activity
- Cephalosporins
- Saccharose phosphate synthetase (SPS), a preparation method and CDNA therefor, and use of the CDNA for modifying SPS expression in plant cells
This invention concerns new derivatives of 1-benzenesulphonyl-2-oxo-5-alkoxypyrrolidine, processes for their preparation, pharmaceutical compositons containing them and a method for using them.
In one aspect the invention relates to compounds having the general formula (I): ##STR1## in which R' represents a hydrogen atom, a linear, branched or cyclic alkyl radical containing up to 8 carbon atoms, an alkenyl radical containing from 2 to 8 carbon atoms, an acyl radical containing from 1 to 6 carbon atoms or an aralkyl radical containing from 7 to 15 carbon atoms; and R represents an aryl radical containing up to 14 carbon atoms, possibly substituted, or a possibly substituted mono- or polycyclic aromatic heterocyclic radical.
Preferred alkyl radicals are radicals containing from 1 to 6 carbon atoms, for example, one of the following radicals: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertbutyl, n-pentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
Preferred alkenyl radicals are ethenyl, propenyl or butenyl radicals.
Preferred acyl radicals are acetyl, propionyl or butyryl radicals.
Preferred aralkyl radicals are benzyl or phenethyl radicals.
Preferred aryl radicals are phenyl or naphthyl radicals.
Preferred heterocyclic radicals are the following radicals: furyl, pyranyl, pyridyl, benzofuranyl, isobenzofuranyl, chromanyl, isochromanyl, chromenyl, xanthenyl, phenoxathienyl, oxazolyl, isoxazolyl, furazanyl, phenoxazinyl, thieno(2,3-b)-furanyl, 2H-furo(3,2-b)pyranyl, benzoxazolyl or morpholinyl.
When the R radical is substituted, it has as substituents preferably one or more substituents chosen from the group constituted by free, esterified or etherified hydroxyl radicals in which the ester or ether part contains from 1 to 18 carbon atoms, as for example an acetoxy radical, a methoxy radical or a benzyloxy radical; carbonyl and oximino radicals; linear, branched or cyclized alkyl radicals, saturated or unsaturated, containing up to 18 carbon atoms, for example, a methyl, ethyl, propyl or isopropyl radical; an ethenyl radical or an ethynyl radical; halogen atoms, such as fluorine, chlorine, bromine; the following groups: CF.sub.3, SCF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2 or C.tbd.N; a phenyl radical; acyl and alkoxycarbonyl groups containing from 2 to 8 carbon atoms; and alkylsulphonyl groups containing from 1 to 6 carbon atoms.
Paricularly preferred are compounds of the formula (I) in which R represents a phenyl radical possibly substituted by an alkoxy radical containing up to 4 carbon atoms.
Also particularly preferred are compounds of the formula (I) in which R' represents a linear, branched or cyclic alkyl radical containing up to 8 carbon atoms and more particularly an ethyl radical.
Specially preferred is 1-(benzenesulphonyl)-2-oxo-5-ethoxypyrrolidine.
Other preferred compounds are 1-(4-nitrobenzenesulphonyl)-2-oxo-5-ethoxypyrrolidine, 1-(benzenesulphonyl)-2-oxo-5-isopropoxypyrrolidine, and 1-(benzenesulphonyl)-2-oxo-5-propoxypyrrolidine.
The compounds of the invention exhibit useful pharmacological properties: they delay extinction of the conditioned avoidance response and disappearance of the learned response. They improve or enhance mental alertness, memory and the ability to concentrate.
Another aspect of the invention relates to a method for treating intellectual or nervous asthenias and memory failures of old age or of intellectual fatigue with a compound of the formula (I), particularly the compound of Example 1, as well as the compounds of Examples 14, 35 and 36.
The normal posology is variable according to the condition in question, the subject treated and the route of administration. The dosage can comprise between 50 mg and 3000 mg/day, for example, between 150 and 1500 mg/day in one or more doses for the compound of Example 1 administered by the oral route.
In another aspect the present invention relates to pharmaceutical compositions containing as the active principle or ingredient at least one compound of the formula (I). The pharmaceutical compositions of the invention can be solid or liquid and present themselves in the pharmaceutical forms currently used in human medicine, as for example, simple and sugar-coated tablets, capsules, granules, suppositories, injectable preparations; they are prepared according to the usual methods.
The active principle or principles can be incorporated in the excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various moisturizing, dispersing or emulsifying agents, and preservatives.
In yet another aspect the invention relates to a process for preparing compounds of the formula (I), characterized in that a compound of the formula (II): ##STR2## in which R' has the same meaning as previously, is reacted with a compound of the formula (III): in which Hal represents a chlorine or bromine atom and R has the same meaning as previously, so as to obtain the corresponding compound with the formula (I).
In a preferred means of effecting the process of the invention, the reaction between the product of the formula (II) and the product of the formula (III) is carried out in the presence of a strong base such as butyllithium, an alkaline hydride, such as sodium hydride or sodium bis-(trimethylsilyl)amide; and in a solvent chosen from the group constituted by tetrahydrofuran, benzene, dimethylformamide, dimethylsulphoxide, monoethyl ether of diethylene glycol, or diethyl ether of diethylene glycol.
For the preparation of compounds of the formula (I) in which R represents an aryl radical substituted by one or more amino or hydroxy radicals, the corresponding compounds of the formula (I) in which R represents respectively one or more etherified nitro or hydroxy radicals are reduced. Preferably, the reduction is carried out with hydrogen in the presence of a palladium catalyst in an organic solvent, preferably ethanol.
Compounds of the formula (I), in which R is defined as previously and R' represents a hydrogen atom or an acyl radical containing from 1 to 6 carbon atoms, can be prepared from a halogenide or 4-pentenoyl of the formula (IV): ##STR3## in which Hal represents a halogen atom, by reaction in the presence of a condensation agent with a compound with the formula (V):
H.sub.2 N--SO.sub.2 --R (V)
to obtain a compound of the formula (VI): ##STR4## which is cyclized to obtain the corresponding sulphonamide compound of the formula (I), in which R' represents a hydrogen atom: ##STR5## which is acylated, if desired, to obtain the corresponding compound of the formula (I), in which R' represents an acyl radical: ##STR6##
In a preferred way of effecting the above process, the reaction of the compound of the formula (IV) with the compound of the formula (V) is carried out in the presence of phosphorus oxychloride or thionyl chloride. The cyclization of the compound of the formula (VI) is carried out by reaction with osmium tetraoxide and sodium metaperiodate in sequence, or by the action of ozone. Possible reactive substituents of the radical R are protected at the time of condensation and of cyclization, then deprotected afterwards, according to methods known to those skilled in the art.
The compounds of the formula (II) used as starting materials are known compounds which can be prepared according to the process described in Tetrahedron 31, 1437 (1975) or Tetrahedron 41, 2007 (1985). The preparation of other starting materials is described and illustrated in the examples which follow.
The following examples illustrate the invention without limiting it.
Example 1 : 1-benzenesulphonyl-2-oxo-5-ethoxypyrrolidineTo 4.5 g of 5-ethoxypyrrolidin-2-one dissolved in 140 cm.sup.3 of anhydrous tetrahydrofuran, 21.8 cm.sup.3 of butyl-lithium in hexane (1.6M) is added drop by drop under an inert atmosphere, while cooling to about -10.degree. C. After 45 minutes, 6.15 g of benzenesulphonyl chloride in tetrahydrofuran is added, and the whole is kept at -10.degree. C. under agitation for 2 hours. It is then returned to ambient temperature, and the residue, after concentrating under reduced pressure, is taken up in 100.degree. ethanol. By cooling and under agitation, the product precipitates, and is then filtered, washed abundantly with water, dried, and 2.8 g of the expected product is obtained after crystallizing from isopropanol, m.p. 112.degree.-113.degree. C.
AnalysisCalculated: C % 53.52, H % 5.61, N % 5.20; Found: 53.30, 5.64, 5.10.
Example 2: 1-(4-methoxybenzenesulphonyl)-2-oxo-5-ethoxypyrrolidine.By operating as in example 1, starting with 5.2 g of paramethoxy benzenesulphonyl chloride, the expected product is obtained which is chromato-graphed on silica (eluent: benzene-ethyl acetate 5-2), and 1.5 g of the expected product is obtained. M.p. 112.degree.-113.degree. C., after re-crystallizing from isopropanol.
AnalysisCalculated: C % 52.16, H % 5.72, N % 4.68; Found: 52.21, 5.71, 4.62.
Examples 3 to 46:By operating in a similar manner to that described for example 1 or example 2, the products appearing in the following table have been prepared. In these tables there are shown the physical constants and analyses of the products, as well as the principle characteristics of the operational methods used.
3 TABLE 1
##STR7##
Obtaining I Analysis Ex. alc R + BuLi + III Chromate solv. cryst.
Yield F..degree.
C. C % H % N %
3 Et
##STR8##
-25.degree. C.25 mm -38.degree. C.20 mm -- toluene 1CH.sub.3 CO.sub.2
Et 1 isopropanol 46% 59-61 Calcul.Found 48.8748.69 5.225.08 10.36 10.17
4 Et
##STR9##
-40.degree.
C.25 mm
##STR10##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 34% 77-79 Calcul.Found
41.4841.54 3.233.14 3.453.43
5Et
##STR11##
-30.degree.
C.30 mm
##STR12##
##STR13##
-- isopropanol 42% 110-111 Calcul.Found 4242.37 3.523.43 3.763.69 6
Et
##STR14##
-20.degree.
C.35 mm
##STR15##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 23% 104-105 Calcul.Found 4
2.61 42.47 3.873.77 4.144.05
7 Et
##STR16##
-20.degree.
C.40 mm
##STR17##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 22.8% 83-84 Calcul.Found 4
5.8546.09 4.484.61 3.913.98
8 Et
##STR18##
-15.degree.
C.40 mm
##STR19##
-- toluene 2CH.sub.3 CO.sub.2 Et 8 cyclohexane 23% 58-59 Calcul.Found
46.2946.08 4.184.07 4.154.37
9 Et
##STR20##
-15.degree. C.40 mm -28.degree. C.1 h -- benzene 8CH.sub.3 CO.sub.2 Et
2 isopropanol 28% 75-77 Calcul.Found 47.4447.39 4.644.69 4.614.55 10
Et
##STR21##
-15.degree.
C.40 mm
##STR22##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 40% 113-115 Calcul.Found 5
0.1650.25 4.914.99 4.874.86
11 Et
##STR23##
-25.degree.
C.40 mm
##STR24##
##STR25##
-- isopropanol 27% 120-122 Calcul.Found 47.4447.52 4.644.66 4.614.56
12 Et
##STR26##
-15.degree.
C.40 mm
##STR27##
-- toluene 8CH.sub.3 CO.sub.2
Et 2 isopropanol 28.6% 147-149 Calcul.Found 55.1055.28 6.05 6.21
4.945.12
13 Et
##STR28##
-20.degree.
C.20 mm
##STR29##
##STR30##
toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 28.6% 147-149 Calcul.Found
55.1055.28 6.056.21 4.945.12
14 Et
##STR31##
-20.degree. C.35 mm -50.degree.
C.30 mm
##STR32##
-- EtOH 51% 125-126 Calcul.Found 45.8545.93 4.484.44 8.919.06 15 Et
##STR33##
-20.degree. C.20 mm -20.degree.
C.1 h
##STR34##
-- EtOH 28% 110 Calcul. Found 60.1768.07 5.365.22 4.384.46 16 Et
##STR35##
-20.degree.
C.20 mm
##STR36##
##STR37##
-- isopropanol 39% 139-140 Calcul.Found 60.1760.12 5.365.31 4.384.22
17 Et
##STR38##
-30.degree.
C.20 mm
##STR39##
+MeOH toluene 8CH.sub.3 CO.sub.2
Et 2 isopropanol 29% 74-76 Calcul.Found 46.3446.49 5.055.04 5.405.42
18 Et
##STR40##
-20.degree. C.20 mm -20.degree. C.15 mm -- toluene 8CH.sub.3 CO.sub.2
Et 2 CHCl.sub.3 10% 59-60 Calcul.Found 48.61 48.69 5.165.08 10.2910.17
19 Et
##STR41##
-25.degree.
C.20 mm
##STR42##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 35% 98-99 Calcul.Found
43.6243.29 4.754.68 5.085.16
20 Et
##STR43##
-20.degree. C.35 mm -30.degree. C.2 h 30 -- benzene 8CH.sub.3 CO.sub.2
Et 2 isopropanol 28% 100-102 Calcul.Found 43.5743.62 4.824.75 5.025.08
21 Et
##STR44##
-20.degree. C.15 mm -20.degree.
C.1 h
##STR45##
-- isopropanol 18.6% 100-101 Calcul.Found 47.6347.44 4.724.64 4.534.61
22 Et
##STR46##
-20.degree.
C.20 mm
##STR47##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 22.6%
98-100 Calcul.Found 45.8546.01 4.484.39 8.918.83
23 Et
##STR48##
-20.degree. C.15 mm -35.degree.
C.1 h
##STR49##
toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 36% 89-90 Calcul.Found 6
62.482.58 5.695.54 4.314.05
24 Et
##STR50##
-23.degree.
C.20 mm
##STR51##
##STR52##
-- isopropanol 25.5% 106-107 Calcul.Found 56.5456.32 6.436.39
4.714.59
25 Et
##STR53##
-25.degree.
C.20 mm
##STR54##
##STR55##
-- isopropanol 35% 100-102 Calcul.Found 56.5456.31 6.436.50 4.714.65
26 Et
##STR56##
-35.degree.
C.20 mm
##STR57##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 -- 43% -- Calcul.Found 52.1651.88
5.725.66 4.674.56
27 Et
##STR58##
-20.degree. C.35 mm -25.degree. C.1 h +H.sub.2 O -- EtOH 17.7% 153-154 C
alcul.Found 45.1244.96 4.964.98 4.224.03
28 Et
##STR59##
-20.degree. C.15 mm -20.degree.
C.1 h
##STR60##
toluene 6CH.sub.3 CO.sub.2
Et 4 isopropanol -- -- Calcul.Found 54.0054.12 5.505.48 4.504.37 29
Et
##STR61##
-28.degree.
C.20 mm
##STR62##
##STR63##
-- isopropanol 29% 101-102 Calcul.Found 51.3651.43 5.235.17 4.274.16
30 Et
##STR64##
-30.degree.
C.20 mm
##STR65##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 33.6% 57-59 Calcul.Found 5
0.1649.94 4.914.93 4.874.73
31 Et
##STR66##
-25.degree.
C.20 mm
##STR67##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 36% 117-120 Calcul.Found 6
2.5862.77 5.545.39 4.053.97
32 Et
##STR68##
-35.degree.
C.20 mm
##STR69##
-- toluene 8CH.sub.3 CO.sub.2 Et 2 isopropanol 29% 94-94 Calcul.Found
46.2946.41 4.184.21 4.154.19
33 Et
##STR70##
-30.degree.
C.20 mm
##STR71##
##STR72##
-- isopropanol 26% 99-101 Calcul.Found 46.2946.04 4.184.32 4.154.06
34 CH.sub.3
##STR73##
-10.degree.
C.30 mm
##STR74##
##STR75##
-- isopropanol 28% 121-123 Calcul.Found 51.7552.03 5.135.24 5.495.58
35 CH(CH.sub.3).sub.2
##STR76##
-10.degree.
C.30 mm
##STR77##
##STR78##
-- EtOH 61% 158-160 Calcul.Found 55.1055.26 6.056.17 4.945.01 36
(CH.sub.2).sub.2
CH.sub.3
##STR79##
-18.degree.
C.30 mm
##STR80##
-- CH.sub.3 CO.sub.2
Et 1n-hexane 1
##STR81##
61% 63.65 Calcul.Found 55.1055.29 6.056.03 4.914.79
37 CH(CH.sub.3).sub.2
##STR82##
-35.degree.
C.20 mm
##STR83##
##STR84##
CH.sub.3 CO.sub.2 Et 1n-hexane 2 EtOH 42.9% 153-154 Calcul.Found
47.5547.39 4.914.88 8.538.61
38 CH(CH.sub.3).sub.2
##STR85##
-35.degree. C.30 mm 35.degree.
C.30 mm
##STR86##
-- EtOH 43.02% 135-137 Calcul.Found 63.4963.41 5.895.83 3.903.97 39
(CH.sub. 2).sub.3
CH.sub.3
##STR87##
-47.degree.
C.30 mm
##STR88##
-- CH.sub.3 CO.sub.2
Et
##STR89##
31.70% 46-48 Calcul.Found 56.5456.61 6.446.39 4.714.68
40
##STR90##
##STR91##
-32.degree.
C.20 mm
##STR92##
##STR93##
--
##STR94##
54.7% 96-97 Calcul.Found 58.2358.05 6.196.16 4.534.76
41
##STR95##
##STR96##
-32.degree.
C.20 mm
##STR97##
##STR98##
--
##STR99##
28% 108-109 Calcul.Found 59.4259.21 6.546.66 4.334.29
42 (CH.sub.2).sub.4
CH.sub.3
##STR100##
-35.degree.
C.
##STR101##
-- CH.sub.3 CO.sub.2 Et 1n-hexane 2 -- 75.7% -- Calcul.Found 57.8558.02 6
.806.74 4.504.63 43 (CH.sub.2).sub.5
CH.sub.3
##STR102##
-35.degree.
C.
##STR103##
-- CH.sub.3 CO.sub.2
Et 1n-hexane 2 -- 32%
##STR104##
Calcul.Found 59.0558.94 7.126.99 4.304.15 44 CH.sub.2
CH(CH.sub.3).sub.2
##STR105##
-35.degree.
C.20 mm
##STR106##
CH.sub.3 CO.sub.2
Et 1n-hexane 2 -- 67.2% 70- 71 Calcul.Found 56.5456.36 6.446.51
4.714.76
45 CH(CH.sub.3).sub.2
##STR107##
-35.degree.
C.20 mm
##STR108##
##STR109##
-- isopropanol 52.9% 97-98
46 CH(CH.sub.3).sub.2
##STR110##
-35.degree.
C.20 mm
##STR111##
##STR112##
-- -- 24.4% 101-102
46 CH(CH.sub.3).sub.2
##STR113##
-35.degree.
C.20 mm
##STR114##
##STR115##
-- -- -- --
Example 47: 1-(4-hydroxybenzenesulphonyl)-2-oxo-5-ethoxypyrrolidine.
At 20.degree. C., and under 1000 mbar, 6.3 g of 1-(4-benzyloxyphenylsulphonyl)-5-ethoxypyrrolidin-2-one is hydrogenated in the presence of 1.2 g of catalyst (Pd at 10%), in 150 cm.sup.3 of 96.degree. ethanol. After filtering, concentrating the filtrate, and crystallizing the residue from 96.degree. ethanol, 2.5 g of the expected product is obtained, m.p. 162.degree.-163.degree. C.
AnalysisCalculated: C % 50.51, H % 5.30, N % 4.90; Found: 50.70, 5.21, 5.01.
Example 48: 1-(4-aminobenzenesulphonyl)-2-oxo-5-ethoxypyrrolidine.At ambient temperature and pressure, 4.5 g of 1-(4-nitrophenylsulphonyl)-5-ethoxypyrrolidin-2-one, dissolved in 200 cm.sup.3 of 96.degree. ethanol is hydrogenated in the presence of palladium at 10% on charcoal. The insoluble matter is filtered off and taken up with hot chloroform, filtered, and the last filtrate is added to the alcohol solution resulting from the first filtration. After re-crystallizing the residue twice from 96.degree. ethanol, 2.3 g of the expected product is obtained, m.p. 185.degree.-186.degree. C.
AnalysisCalculated: C % 50.69, H % 5.67, N % 9.85; Found: 50.45, 5.57, 9.79.
Example 49: 1-benzenesulphonyl-2-oxo-5-benzyloxypyrrolidineAt ambient temperature and under an inert atmosphere, 4.40 g of 5-benzyloxypyrrolidin-2-one is added to a solution of 4.64 g of sodium bis(trimethylsilyl) amide in 350 cm.sup.3 of anhydrous ethyl ether. The mixture is agitated for 30 minutes, then cooled to 0.degree. C., and a solution of 4.06 g of benzenesulphonyl chloride in 30 cm.sup.3 of anhydrous ether is added, while maintaining the temperature at 0.degree. C. The temperature is allowed to return to the ambient, then, after filtering and evaporating the solvent under reduced pressure, the residue is chromatographed on silica, eluting with a mixture of ethyl acetate and n-hexane (1-2). After re-crystallizing from a mixture of benzene and n-hexane (1-3), 2.25 g of the expected product is obtained, m.p. 80.degree.-81.degree. C.
AnalysisC.sub.17 H.sub.17 NO.sub.4 S Calculated: C % 61.61, H % 5.17, N % 4.23; Found: 61.39, 5.23, 4.31.
Example 50: 1-benzenesulphonyl-2-oxo-5-(propen-2-yloxy)pyrrolidineThe operation is done as in example 49, starting with 0.80 g of 5-(2-propenyloxy)pyrrolidin-2-one. After cooling to -10.degree. C., a solution of 1.00 g of benzenesulphonyl chloride in 10 cm.sup.3 of anhydrous ether is added and the temperature is maintained at -10.degree. C. 100 cm.sup.3 of ethyl acetate is added before filtering. Elution is done with a mixture of ethyl acetate and hexane (1-1) and by re-crystallizing from isopropyl ether, 0.20 g of product is obtained, m.p. 54.degree.-56.degree. C.
AnalysisC.sub.13 H.sub.15 NO.sub.4 S Calculated: C % 55.50, H % 5.37, N % 4.98; Found: 55.62, 5.28, 5.01. Preparation of 5-(2-propenyloxy)pyrrolidin-2one).
2.5 g of 5-hydroxypyrrolidin-2-one and 1.25 g of Amberlite IR 120 (H) resin are heated to 65.degree. C. for 1 hour 30 minutes in 55 cm.sup.3 of allyl alcohol. After allowing to return to ambient temperature, the alcohol is evaporated under reduced pressure and the residue is chromatographed on silica, eluting with ethyl acetate. 0.90 g of the expected product is obtained.
AnalysisC.sub.7 H.sub.11 NO.sub.2 Calculated: C % 59.56, H % 7.85, N % 9.92; Found: 57.81, 7.75, 9.10.
Example 51: 1-benzenesulphonyl-2-oxo-5-hydroxypyrrolidine50 mg of osmium tetraoxide is added to a solution of 5 g of N-benzenesulphonyl-4-pentenoylamide in 150 cm.sup.3 of dioxan and 50 cm.sup.3 of water. After about 20 minutes, 5.10 g of sodium metaperiodate is added, and after agitating for 1 hour, a further 5.10 g of sodium metaperiodate is added, with agitation for a further 2 hours at ambient temperature. The precipitate formed is filtered off, the filtrate is evaporated to dryness and the residue is dissolved in 50 cm.sup.3 of ethyl acetate, treated with activated charcoal, then evaporated to dryness. The residue is triturated in anhydrous ethyl ether, and 2.05 g of the expected product is obtained, which is re-crystallizxed from isopropanol m.p. 121.degree. C.
AnalysisC.sub.10 H.sub.11 NO.sub.4 S, MW: 241.27; Calculated: C % 49.78, H % 4.59, N % 5.80; Found: 49.69, 4.46, 5.89.
The N-benzenesulphonyl-4-pentenoylamide used in example 51 has been prepared as follows.
2.4 g of 4-pentenoyl chloride (Tetrahedron 32, 1085 (1976)) and 2.65 g of benzenesulphonamide in 5 cm.sup.3 of phosphorus oxychloride are agitated for 20 hours at ambient temperature. The solution obtained is evaporated carefully to dryness under reduced pressure, and 4 g of the expected product is obtained. This product is used as it is.
Example 52: 1-benzenesylfonyl-2-oxo-5-acetoxypyrrolidine.2.90 g of 1-benzenesulphonyl-5-hydroxypyrrolidin-2-one is heated to reflux for one-and-a-half hours in 58 cm.sup.3 of acetic anhydride. After allowing this to cool to ambient temperature, the solvent is evaporated under reduced pressure while forming the azeotrope acetic anhydride-toluene. The residue is crystallized from 95.degree. ethanol, and 2.45 g of the expected product is obtained, m.p. 153.degree.-155.degree. C.
AnalysisC.sub.12 H.sub.13 NO.sub.5 S, MW. 283.31; Calculated: C % 50.85, H % 4.62, N % 4.94; Found: 51.04, 4.49, 5.12. Preparation of the 5-isopropoxy pyrrolidin-2-one used as starting materials in examples 35 and 37.
28.64 g of succinimide in 1200 cm.sup.3 of isopropanol is cooled to -10.degree. C., 32.80 g of sodium borohydride is added, with agitation for four hours, while the temperature is kept between -10.degree. C. and 0.degree. C. and while adding every 15 minutes 15 drops of a 2N solution of hydrochloric acid in isopropanol. Then, between 0.degree. and 2.degree. C., the ph is adjusted to 2-3 by adding a 2N solution of hydrochloric acid in isopropanol, and agitation is continued for 2 hours at this temperature. Finally, at 0.degree. C., the solution is neutralized by means of a solution of potassium hydroxide in isopropanol. The solvent is evaporated under reduced pressure, extraction is done with chloroform, the extracts are concentrated to dryness under reduced pressure, and 20.5 g of the expected product is obtained, m.p. 68.degree.-71.degree. C. Preparation of the 5-propoxy pyrrolidin-2-one used as starting materials in example 36.
The operation is done in a similar manner, with n-propanol instead of isopropanol. 16 g of sodium borohydride is used and cooled to -7.degree.-0.degree. C. 27.50 g of the expected product is obtained, m.p. 52.degree.-54.degree. C. Preparation of the 5-methoxy pyrrolidin-2-one used at the start of example 34 and of the 5-butoxy pyrrolidin-2-one used at the start of example 39. Synthesis (4) 315-317 (1980) (technique with sodium borohydride). Preparation of the benzyloxyphenylsulphonyl used as starting materials in example 13
(a) Sodium benzyloxyphenylsulphonate
For 30 minutes at ambient temperature, 30 g of the sodium salt of bihydrated paraphenolsulphonic acid is agitated in 49 cm.sup.3 of a 15% aqueous solution of sodium hydroxide. A solution of 27.95 g of benzyl bromide in 60 cm.sup.3 of ethanol is added, and the whole is heated to reflux for 5 hours. After leaving to rest for one night, 34.3 g of the expected product is filtered off.
(b) Benzyloxyphenylsulphonyl chloride
34.3 g of the product obtained above is mixed with 430 cm.sup.3 of methylene chloride, 24.95 g of phosphorus pentachloride is added and the whole is heated to reflux for 7 hours. It is then taken to dryness under reduced pressure and extracted with anhydrous toluene. The solvent is evaporated off and the residue is recrystallized from isopropyl ether and filtered hot on activated charcoal. 23.95 g of the expected product is obtained, m.p. 101.degree.-103.degree. C. Preparation of 5-isobutoxy pyrrolidin-2-one.
2.5 g of 5-hydroxy pyrrolidin-2-one and 1.25 g of Amberlite resin IR-120 (H) are heated to 65.degree. C. for 3 hours in 55 cm.sup.3 of isobutanol. After allowing to return to ambient temperature, filtering off the resin and distilling off the solvent under reduced pressure, a residue is obtained which is chromatographed on silica, eluting with ethyhtgl acetate, and 2.90 g of the expected product is obtained, m.p. 30.degree.-32.degree. C.
AnalysisC.sub.8 H.sub.15 NO.sub.2 Calculated: C % 61.12, H % 9.62, N % 8.91; Found: 60.87, 9.54, 8.83.
5-pentyloxy pyrrolidin-2-one, 5-cyclopentyloxy pyrrolidin-2-one, 5-benzyloxy pyrrolidin-2-one, 5-hexyloxy pyrrolidin-2-one, 5-cyclohexyloxy pyrrolidin-2-one: these products have also been prepared as above, by using Amberlite resin and the appropriate alcohol. (See following table).
TABLE II
__________________________________________________________________________
R reaction
cryst.
chromato
F .degree.C.
cryst.
Yield
__________________________________________________________________________
pentyl
65.degree. C. 3 h
CH.sub.3 CO.sub.2 Et
42-43 63,4%
cyclopentyl
65.degree. C. 3 h
CH.sub.3 CO.sub.2 Et
87-89
90-91.degree. C.
61,7%
isopropanol
benzyl
60.degree. C. 3 h
n-hexane 3
-- 80-82 72,1%
benz 1
hexyl 60.degree. C. 3 h
CH.sub.3 CO.sub.2 Et
68,2%
cyclohexyl
60.degree. C. 3 h
CH.sub.3 CO.sub.2 Et
85-7
95-96.degree. C.
41,38%
__________________________________________________________________________
Examples of pharmaceutical compositions
(a) Tablets have been prepared responding to the following formula:
Product of example 1; 100 mg
Excipient q.s. for a tablet finished at; 300 mg
(Detail of excipient: lactose, corn starch, treated starch, rice starch, magnesium stearate, talc).
(b) Capsules responding to the following formula have been prepared:
Product of example 1; 200 mg
Excipient q.s. for a capsule finished at; 300 mg
(detail of excipient: talc, magnesium stearate, aerosil)
PHARMACOLOGICAL STUDY Acute toxicity and behaviourWe used male mice (CD.sub.1 Charles River) weighing 22-23 g and without food for 16 hours. The products were administered normally by oral route at doses of 1000-500-250 mgd/kg.
The effect of the products on the behaviour of the animals was evaluated according to the method described by Irvin (Psychopharmacologia 13,222-257, 1968) during the first 8 hours and on the 24th hour.
The mortality was checked during the 7 days following the treatment.
The LD.sub.50 was thus found greater than 1000 mg/kg for the products of examples 1 to 3, 5, 7 to 10, 14 to 16 and 34 to 36.
Apprenticeship and memorizingWe used male mice (CD.sub.1 Charles Rivers) weighing 25-30 g. The animals were placed in the illuminated part of a box with two compartments communicating by an opening (F. Barzaghi et G. Giuliani, Brit. J. Pharmacol. in course of publication).
At the instant when the mouse passes from the illuminated compartment to the dark compartment, the opening closes and the mouse is punished by an electric discharge to the paws. The animal submitted to this procedure learns to remember the punishment. In fact, if it is put back into the illuminated compartment, it will thus avoid crossing the opening and re-entering the dark compartment.
In order to induce a retrograde amnesia, the animals are submitted to an electric shock immediately after the apprenticeship. After the electric shock, the products are administered by oral route at doses of 6.25; 12.5; 25; 50; 100; 200; and 400 mg/kg.
We used 10 to 50 animals per dose.
The anti-amnesic effect of the products is evaluated 3 hours after the treatment, by using the same procedure as that used for the acquisition.
The time taken by the animal to return to the dark chamber (time limit 180 seconds) is used as the evaluation parameter.
In the same experimental conditions, the control animals entered with a time lapse of 40-50 seconds.
The active products are those which cause a significant increase in the latency time with a bell-shaped dose-response curve.
The results are expressed as percentages of increase in the latency time, in comparison with the corresponding controls.
The results are given over page.
The products of examples 1 to 3, 5, 7 to 10, 12, 14, 16, 18, 31, 34 to 37 and 48 showed an anti-amnesic activity at doses between 25 and 200 mg/kg.
In particular, the products of examples 1, 14, 35, 36 and 37 induced a very notable improvement in the performance of the animals over a wide scale of doses.
TABLE III
______________________________________
Percentage of increase of the latency time
in comparison with the controls
DOSE:mg/kg:os
Product of example
200 100 50 25 12,5
______________________________________
1 +109* +132* +118* +95* +79*
2 +23 +64* +25 +22 --
3 +7 +58* +2 +5 0
5 +75* +44 0 +11 +28
7 +108* +52* +31 +27 +6
8 +75* +53* +41 0 +24
9 +91* +16 +30 +25 +23
10 +65* +18 +21 0 +14
12 +59* +21 +8 0 0
14 +98* +99* +47* +42 0
48 0 +72* +28 +23 +11
15 +65* +39 0 +14 0
16 +47* +23 +20 0 0
31 +75* +79* +65* +31 0
34 +105* +69* +23 0 0
35 + 65* +72* +95* +54* +4
37 +198* +95* +82* +34 --
36 +82* +72* +98* +50* +7
18 +88* +49 +36 +21
Pyrocetam 20 48* 10 19 --
Antracetam 32 88* 77* 39 --
______________________________________
*Values notably different in comparison with the controls.
Claims
1. A compound of the formula ##STR116## wherein R' represents a hydrogen atom, a linear, branched or cyclic alkyl radical containing up to 8 carbon atoms, an alkenyl radical containing from 2 to 8 carbon atoms, an alkanoyl radical containing from 1 to 6 carbon atoms or an aralkyl radical containing from 7 to 15 carbon atoms; and R represents an unsubstituted phenyl, or a phenyl substituted with an alkoxy radical containing up to 4 carbon atoms, an OH radical, one or more radicals selected from the group consisting of F, Cl and CF.sub.3, a nitro radical, a benzyloxy radical, a phenyl radical, an NH.sub.2 radical, one or more methyl radicals, a SO.sub.2 CH.sub.3 radical, a COCH.sub.3 radical, a CO.sub.2 CH.sub.3 radical or R is a radical selected from the group consisting of ##STR117##
2. A compound according to claim 1, wherein R' represents a linear, branched or cyclic alkyl radical containing up to 8 carbon atoms.
3. A compound according to claim 2, wherein R' is ethyl.
4. A compound according to claim 1, which is 1-(benzenesulphonyl)-2-oxo-5-ethoxypyrrolidine.
5. A compound according to claim 1, which is 1-(4-nitrobenzenesulphonyl)-2-oxo-5-ethoxypyrrolidine.
6. A compound according to claim 1, which is 1-(benzenesulfonyl)-2-oxo-5-isopropoxypyrrolidine.
7. A compound according claim 1, which is 1-(benzenesulfonyl)-2-oxo-5-propoxypyrrolidine.
8. An anti-amnesia composition comprising an anti-amnesia effective amount of a compound according to claim 1, together with a pharmaceutically acceptable carrier.
9. An anti-amnesic composition comprising an anti-amnesia effective amount of a compound selected from the group consisting of 1-(benzenesulfonyl)-2-oxo-5-ethoxypyrrolidine, 1-(4-nitrobenzene-sulfonyl)-2-oxo-5-ethoxypyrrolidine, 1-(benzenesulfonyl)-2-oxo-5-isopropoxypyrrolidine and 1-(benzenesulphonyl)-2-oxo-5-propoxypyrrolidine, together with a pharmaceutically acceptable carrier.
10. A method for treating amnesia or memory failure which comprises administering an effective amount of a compound according to claim 1 to a patient suffering from amnesia or memory failure.
| 3117975 | January 1964 | Boytnick et al. |
| 0138721 | April 1985 | EPX |
- Drugs of the Future, vol. 10, No. 1985, pp. 972, 974.
Type: Grant
Filed: Dec 29, 1986
Date of Patent: May 9, 1989
Assignee: Roussel Uclaf (Paris)
Inventors: Emilio Toja (Milan), Carlo Gorini (Milan), Carlo Zirotti (Arona), Fernando Barzaghi (Monza, Milan), Giulio Galliani (Monza, Milan)
Primary Examiner: David B. Springer
Law Firm: Stevens, Davis, Miller & Mosher
Application Number: 6/947,270
International Classification: C07D207273; C07D40312; A61K 3140;
